Innovation in Drug Discovery

Drug Discovery in Early Research

Cellima Talks II

Drug Discovery in Early Research

Eugenio Fava, an accomplished scientist known for his passion and deep expertise in neuroscience and drug discovery, will share his insights into the drug discovery process, providing insight into the strategic approaches essential to understanding diseases, identifying key targets, and developing effective drugs using cutting-edge technologies.

During our session, Eugenio will provide an in-depth comparison between the roles of academic institutions and pharmaceutical companies in drug discovery, highlighting their unique challenges and contributions.

We will also explore with him the current obstacles researchers face throughout the drug discovery process. In addition, the discussion with Eugenio will address pressing issues in the field, including the critical role of artificial intelligence in drug discovery, the innovative use of 3D cell models, the potential of stem cell technologies, and the application of single-cell techniques to drug screening

Join us for an engaging conversation with Eugenio Fava as we explore the latest trends and challenges in drug discovery, providing a unique opportunity to gain valuable insights from a leading expert in the field.

more insights


HCI 2024 – Prospects

In order to better describe the current state and future prospects of High-Content Imaging, a market survey was conducted among researchers and organizations involved in early drug discovery worldwide.

Read more >
Cell Painting

The Power of Cell Painting & AI

Want to explore the groundbreaking intersection of cell biology and artificial intelligence in drug discovery? I was delighted to have the opportunity to discuss this topic with Niranj Chandrasekaran of the BROAD Institute on January 12, 2024. In this interview, we discussed the transformative role of cell painting and KI technologies in advancing drug discovery.

Read more >
AI in Pharma Research

AI Tools In Pharmaceutical Research

Join us for an exciting discussion on the use of specialized AI tools in early drug discovery. David Egan, CEO of Core Life Analytics and Philipp Kainz, CEO of KML Vision discuss the use of the latest developments in the field of advanced machine learning and deep learning.

Read more >

Future Prospects of High-Content Imaging